Why did RBOT's EPS remain flat throughout 2024?

The EPS of RBOT remained flat throughout 2024 due to a combination of factors:

1. **Revenue Growth**: RBOT's Total Revenue (Cum) for 2024 was not provided, but the company's R&D Expenses (Cum) for the same period were reported at $40.16 million. The increase in R&D expenses, which is a key component of operating expenses, without a corresponding increase in revenue, could indicate that the company is investing more in developing its products and services.
2. **Net Margin**: The Net Margin of RBOT for 2024 was not provided. However, a decrease in net margin could indicate that the company's expenses, including R&D and SG&A, are increasing, which could be a factor in the flat EPS.
3. **Strategic Investments**: RBOT has been making significant progress towards delivering the first version of their single port platform. These strategic investments in research and development and the integration of the system are likely contributing to the flat EPS as these expenses are not yet offset by revenue from the new platform.
4. **Clinical Trials**: The company is planning to treat the first clinical patient within a year, which is a significant milestone but also indicates that the company is still in the early stages of clinical validation. The costs associated with clinical trials and the preparation for market launch are likely impacting the EPS.

In conclusion, the flat EPS of RBOT throughout 2024 can be attributed to a combination of increased R&D expenses, strategic investments in platform development, and the preparation for clinical trials, which have not yet translated into significant revenue growth.